Ischaemic heart disease in patients with cancer

被引:10
作者
Ameri, Pietro [1 ,2 ]
Bertero, Edoardo [2 ,3 ]
Lombardi, Marco [2 ,4 ]
Porto, Italo [1 ,2 ]
Canepa, Marco [1 ,2 ]
Nohria, Anju [5 ]
Vergallo, Rocco [1 ,2 ]
Lyon, Alexander R. [6 ]
Lopez-Fernandez, Teresa [7 ,8 ]
机构
[1] IRCCS Osped Policlin San Martino, Cardiovasc Dis Unit, Genoa, Italy
[2] Univ Genoa, Dept Internal Med, Viale Benedetto XV 6, I-16132 Genoa, Italy
[3] Univ Clin Wurzburg, Comprehens Heart Failure Ctr CHFC, Wurzburg, Germany
[4] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Dept Cardiovasc Sci, Rome, Italy
[5] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA USA
[6] Royal Brompton Hosp, Cardiooncol Serv, London, England
[7] Paz Univ Hosp, IdiPAZ Res Inst, Cardiol Dept, Madrid, Spain
[8] Quiron Pozuelo Univ Hosp, Cardiol Dept, Madrid, Spain
关键词
Ischaemic heart disease; Myocardial infarction; Percutaneous coronary intervention; Cancer; Mechanism; Cardio-oncology; DUAL ANTIPLATELET THERAPY; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY-DISEASE; CLONAL HEMATOPOIESIS; BREAST-CANCER; CARDIOVASCULAR-DISEASE; STENT IMPLANTATION; BYPASS SURGERY; RISK-FACTORS; INFLAMMATION;
D O I
10.1093/eurheartj/ehae047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Graphical Abstract The occurrence of IHD in cancer patients is due to many factors. Three main drivers are CV risk factors, inflammation, and ageing, which promote both diseases. Risk factors and ageing act via specific pathways and induction of chronic, systemic inflammation. Microbiome and hormonal alterations are variably interconnected with risk factors and ageing, and also contribute to the development of IHD and cancer. Moreover, a role is played by the genetic background. CTR-CVT can cause or facilitate IHD, and experimental evidence indicates that IHD and cancer fuel one another. Social determinants of health represent non-biological factors further favouring the association between the two conditions. For the clinician, the coexistence of IHD and cancer is challenging, as outcomes are worse and evidence from RCTs is limited. The forest plot in the right panel shows the increased incidence rate ratio of all-cause mortality in patients undergoing percutaneous coronary intervention with vs. without cancer. CHIP, clonal haematopoiesis of indeterminate potential; CI, confidence interval; CTR-CVT, cancer treatment-related cardiovascular toxicity; CV, cardiovascular; ECM, extracellular matrix; IHD, ischaemic heart disease; IRR, incidence rate ratio; RCT, randomized controlled trial. Cardiologists are encountering a growing number of cancer patients with ischaemic heart disease (IHD). Several factors account for the interrelationship between these two conditions, in addition to improving survival rates in the cancer population. Established cardiovascular (CV) risk factors, such as hypercholesterolaemia and obesity, predispose to both IHD and cancer, through specific mechanisms and via low-grade, systemic inflammation. This latter is also fuelled by clonal haematopoiesis of indeterminate potential. Furthermore, experimental work indicates that IHD and cancer can promote one another, and the CV or metabolic toxicity of anticancer therapies can lead to IHD. The connections between IHD and cancer are reinforced by social determinants of health, non-medical factors that modify health outcomes and comprise individual and societal domains, including economic stability, educational and healthcare access and quality, neighbourhood and built environment, and social and community context. Management of IHD in cancer patients is often challenging, due to atypical presentation, increased bleeding and ischaemic risk, and worse outcomes as compared to patients without cancer. The decision to proceed with coronary revascularization and the choice of antithrombotic therapy can be difficult, particularly in patients with chronic coronary syndromes, necessitating multidisciplinary discussion that considers both general guidelines and specific features on a case by case basis. Randomized controlled trial evidence in cancer patients is very limited and there is urgent need for more data to inform clinical practice. Therefore, coexistence of IHD and cancer raises important scientific and practical questions that call for collaborative efforts from the cardio-oncology, cardiology, and oncology communities.
引用
收藏
页码:1209 / 1223
页数:15
相关论文
共 158 条
  • [31] Global, regional, and national burden of ischaemic heart disease and its attributable risk factors, 1990-2017: results from the Global Burden of Disease Study 2017
    Dai, Haijiang
    Abu Much, Arsalan
    Maor, Elad
    Asher, Elad
    Younis, Arwa
    Xu, Yawen
    Lu, Yao
    Liu, Xinyao
    Shu, Jingxian
    Bragazzi, Nicola Luigi
    [J]. EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2022, 8 (01) : 50 - 60
  • [32] Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
    Darby, Sarah C.
    Ewertz, Marianne
    McGale, Paul
    Bennet, Anna M.
    Blom-Goldman, Ulla
    Bronnum, Dorthe
    Correa, Candace
    Cutter, David
    Gagliardi, Giovanna
    Gigante, Bruna
    Jensen, Maj-Britt
    Nisbet, Andrew
    Peto, Richard
    Rahimi, Kazem
    Taylor, Carolyn
    Hall, Per
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (11) : 987 - 998
  • [33] Body-Mass Index and Mortality among 1.46 Million White Adults.
    de Gonzalez, Amy Berrington
    Hartge, Patricia
    Cerhan, James R.
    Flint, Alan J.
    Hannan, Lindsay
    MacInnis, Robert J.
    Moore, Steven C.
    Tobias, Geoffrey S.
    Anton-Culver, Hoda
    Freeman, Laura Beane
    Beeson, W. Lawrence
    Clipp, Sandra L.
    English, Dallas R.
    Folsom, Aaron R.
    Freedman, D. Michal
    Giles, Graham
    Hakansson, Niclas
    Henderson, Katherine D.
    Hoffman-Bolton, Judith
    Hoppin, Jane A.
    Koenig, Karen L.
    Lee, I-Min
    Linet, Martha S.
    Park, Yikyung
    Pocobelli, Gaia
    Schatzkin, Arthur
    Sesso, Howard D.
    Weiderpass, Elisabete
    Willcox, Bradley J.
    Wolk, Alicja
    Zeleniuch-Jacquotte, Anne
    Willett, Walter C.
    Thun, Michael J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (23) : 2211 - 2219
  • [34] Competing Cardiovascular Outcomes Associated With Subclinical Atherosclerosis (from the Multi-Ethnic Study of Atherosclerosis)
    Desai, Chintan S.
    Ning, Hongyan
    Kang, Joseph
    Folsom, Aaron R.
    Polak, Joseph F.
    Sibley, Christopher T.
    Tracy, Russell
    Lloyd-Jones, Donald M.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2013, 111 (11) : 1541 - 1546
  • [35] Cell-Type-Specific Responses to Interleukin-1 Control Microbial Invasion and Tumor-Elicited Inflammation in Colorectal Cancer
    Dmitrieva-Posocco, Oxana
    Dzutsev, Amiran
    Posocco, David F.
    Hou, Vivianty
    Yuan, Wuxing
    Thovarai, Vishal
    Mufazalov, Ilgiz A.
    Gunzer, Matthias
    Shilovskiy, Igor P.
    Khaitov, Musa R.
    Trinchieri, Giorgio
    Waisman, Ari
    Grivennikov, Sergei, I
    [J]. IMMUNITY, 2019, 50 (01) : 166 - +
  • [36] Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis
    Dolladille, Charles
    Akroun, Julia
    Morice, Pierre-Marie
    Dompmartin, Anne
    Ezine, Emilien
    Sassier, Marion
    Da-Silva, Angelique
    Plane, Anne-Flore
    Legallois, Damien
    L'orphelin, Jean-Mathieu
    Alexandre, Joachim
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 (48) : 4964 - +
  • [37] Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic lschemic Heart Failure
    Dorsheimer, Lena
    Assmus, Birgit
    Rasper, Tina
    Ortmann, Christina A.
    Ecke, Andreas
    Abou-El-Ardat, Khalil
    Schmid, Tobias
    Bruene, Bernhard
    Wagner, Sebastian
    Serve, Hubert
    Hoffmann, Jedrzej
    Seeger, Florian
    Dimmeler, Stefanie
    Zeiher, Andreas M.
    Rieger, Michael A.
    [J]. JAMA CARDIOLOGY, 2019, 4 (01) : 25 - 33
  • [38] Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque
    Drobni, Zsofia D.
    Alvi, Raza M.
    Taron, Jana
    Zafar, Amna
    Murphy, Sean P.
    Rambarat, Paula K.
    Mosarla, Rayma C.
    Lee, Charlotte
    Zlotoff, Daniel A.
    Raghu, Vineet K.
    Hartmann, Sarah E.
    Gilman, Hannah K.
    Gong, Jingyi
    Zubiri, Leyre
    Sullivan, Ryan J.
    Reynolds, Kerry L.
    Mayrhofer, Thomas
    Zhang, Lili
    Hoffmann, Udo
    Neilan, Tomas G.
    [J]. CIRCULATION, 2020, 142 (24) : 2299 - 2311
  • [39] Myocardial infarction accelerates atherosclerosis
    Dutta, Partha
    Courties, Gabriel
    Wei, Ying
    Leuschner, Florian
    Gorbatov, Rostic
    Robbins, Clinton S.
    Iwamoto, Yoshiko
    Thompson, Brian
    Carlson, Alicia L.
    Heidt, Timo
    Majmudar, Maulik D.
    Lasitschka, Felix
    Etzrodt, Martin
    Waterman, Peter
    Waring, Michael T.
    Chicoine, Adam T.
    van der Laan, Anja M.
    Niessen, Hans W. M.
    Piek, Jan J.
    Rubin, Barry B.
    Butany, Jagdish
    Stone, James R.
    Katus, Hugo A.
    Murphy, Sabina A.
    Morrow, David A.
    Sabatine, Marc S.
    Vinegoni, Claudio
    Moskowitz, Michael A.
    Pittet, Mikael J.
    Libby, Peter
    Lin, Charles P.
    Swirski, Filip K.
    Weissleder, Ralph
    Nahrendorf, Matthias
    [J]. NATURE, 2012, 487 (7407) : 325 - 329
  • [40] An Increased Understanding of the Association Between Atherosclerosis and Immune Checkpoint Inhibitors
    Ellison, Judah M.
    Nohria, Anju
    [J]. CURRENT CARDIOLOGY REPORTS, 2023, 25 (08) : 879 - 887